Book a consult

Medical Weight Loss for Men — Southern California

LOSE THE WEIGHT. KEEP THE MUSCLE.

FDA-approved GLP-1 medications · A physician-supervised program built for men

GLP-1 medications changed what’s possible. Supervision decides whether it lasts. At Dr. Vigor® clinics, medical weight loss means FDA-approved medication — never compounded — prescribed after an in-person evaluation with labs, and wrapped in the program that makes it work: nutrition and training guidance built for a man’s physiology, clinician-set monitoring, and a plan for the day you stop. Individual results vary.

Call 949-570-0800 Book a consult
  • FDA-approved medications only
  • Physician-supervised
  • A plan for after

A medical consultation and prescription are required before any medication is provided. Medication is prescribed only when clinically appropriate, and not every man is a candidate. No amount or rate of weight loss is promised.

The results and experiences featured on this site are examples, not promises. Individual results and patient experience vary. A medical consultation and prescription are required before any medication is provided.

Why This Works

The biology was working against you. Now medicine can work on the biology.

Most men who land here have done the diets, and the diets worked — until they didn’t. That isn’t a character problem. Obesity is a medical condition with real biology behind it, and it is common: about four in ten American men have it, and the rate is highest in adults in their forties and fifties.[1] What’s new is that, for the first time, medicine can act directly on the appetite biology that made every diet a fight.

GLP-1 medications work on the receptor for a gut hormone that tells the body it has eaten. Acting on that receptor slows how fast the stomach empties, lowers food intake, and engages the brain circuits that govern appetite — so a normal portion feels like enough, and the constant pull toward the next meal quiets down.[2] One of the approved medications, tirzepatide, acts on a second gut-hormone receptor as well.[3] None of this is grit in a pen. It is pharmacology doing a job that effort alone was never built to do.

Here is the honest pivot, and the whole page hangs on it. The medication changes appetite. It does not decide what a man eats, whether he keeps his muscle while the scale drops, or what happens on the day he stops. That’s the program’s job — and it’s the part most weight-loss websites leave out.

The Program

Four steps, run like medicine

The medication is a tool. The program is what makes the tool work. Every step is set by your own licensed clinician, and nothing is dispensed before the evaluation.

  1. Step 01

    Evaluate and measure

    A focused consult, then an in-person visit: vitals, a physical exam, and baseline bloodwork. Your clinician sets the panel that fits your history — metabolic, cardiovascular, and hormonal markers where they matter, including testosterone when the picture calls for it — and decides whether medication is appropriate for you, against the approved criteria and the conditions that rule it out.[4]

  2. Step 02

    Prescribe and titrate, if appropriate

    An FDA-approved medication chosen for the man in front of the clinician, never off a menu. Dosing starts low and steps up on the label’s schedule — the approved GLP-1 medications are designed to be escalated gradually, a step at a time.[4][3] Your clinician sets the pace.

  3. Step 03

    Check in and adjust

    Weight, measurements, side effects, and dose are reviewed at clinician-set check-ins, with bloodwork repeated on a cadence your clinician sets. The dose moves when your progress and your labs say it should. That loop — measure, adjust, measure again — is the same standard every Dr. Vigor® program runs on.

  4. Step 04

    The off-ramp

    A maintenance plan for keeping it off. The habits built during treatment — protein, training, sleep, the eating pattern that works for you — are the plan, and your clinician sets the course for tapering or continuing. In the trials, most of the lost weight came back after participants stopped — which is why the plan for after is built in from day one, and why we say so up front.[5][6] Weight loss you can’t keep is weight you rented.

The field’s guidelines say the same thing in their own language: medication is an addition to lifestyle care for adults with obesity who haven’t succeeded with diet and exercise alone, not a replacement for it.[7][8] Individual results vary.

Built for Men

Protect what the scale can’t see

The men who do well on these medications are the ones who protect what the scale can’t see. When weight comes off fast, some of it is lean mass — muscle included: in an Eli Lilly-sponsored body-composition study of 160 participants inside one of the pivotal tirzepatide trials, about a quarter of the weight lost was lean mass, and across the wider research the reported share ranges from about a sixth or less to, in some studies, roughly half.[9][10] For a man in his forties or fifties, that’s the difference between looking lean and looking depleted — and between staying strong and not.

So the program pairs the prescription with the two things the evidence says preserve muscle during weight loss. Resistance training: adding it to a weight-loss diet reduces the loss of fat-free mass and increases fat loss without changing the total weight lost, and in older adults it has prevented nearly all of the muscle loss a calorie deficit would otherwise cause.[11][12] Protein: higher-protein eating during energy restriction is associated with modestly greater fat loss and better preservation of lean mass, with targets in the range of roughly 1.2 to 1.6 grams per kilogram per day and a meaningful serving at each meal.[13][14] Our clinical team, under physician supervision, turns that into a training and eating plan you can actually run, built for a man’s schedule and a man’s physiology, along with sleep and habit counsel. And it tracks how your body is changing, not just what it weighs, so the plan is adjusted to what’s actually happening.

One more honest note, because it’s the reason we measure rather than assume. Most of the pivotal GLP-1 trials enrolled mostly women — seven or eight in ten participants in the maintenance trials.[6][15] In the largest trial that was mostly men — adults with heart disease — clinically meaningful weight loss occurred in both sexes, and men lost less than women on average.[16] That’s not a reason for pessimism. It’s a reason to track your numbers instead of quoting someone else’s. Individual results vary.

Sourcing Candor

FDA-approved. Never compounded.

Does Dr. Vigor® use compounded semaglutide or tirzepatide? No. We prescribe only FDA-approved GLP-1 medications, dispensed by state-licensed U.S. pharmacies with a valid prescription. No compounded GLP-1 products, no mystery vials, no exceptions.

Here’s why, straight from the regulator. Compounded drugs are not FDA-approved, which means the FDA does not review them for safety, effectiveness, or quality before they are sold.[17] The drug shortages that once justified compounded copies ended — tirzepatide in December 2024 and semaglutide in February 2025 — and the FDA’s tolerance for compounded copies ended with them.[18] As of the end of May 2026 the FDA had logged 990 adverse-event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide, including hospitalizations that may have come from dosing errors.[17] And in March 2026 the FDA sent warning letters to thirty telehealth companies that marketed compounded products as if they were the same as the approved drugs — its second such wave.[19] We were never going to be on that list.

If supply or pricing changes, we’ll tell you straight — before it affects you.

What’s actually approved, as of this writing. The FDA has approved these GLP-1 medications for weight management in adults with obesity, or overweight with a weight-related condition: Wegovy® (semaglutide) as a weekly injection, including a higher-dose form approved in March 2026, and as a tablet[4][20] · Zepbound® (tirzepatide), a weekly injection[3] · Foundayo™ (orforglipron), a daily tablet approved in April 2026[21][22] · Saxenda® (liraglutide), a daily injection.[23] Which one — if any — fits you is your clinician’s decision at the consult, made against your labs, your history, and your goals. Not against a menu, and not against a marketing budget.

Beyond the GLP-1 Class

Not every man needs a GLP-1 medication — and there are other approved options

A GLP-1 medication isn’t the right tool for every man, and some men don’t need one. There are FDA-approved options beyond the class, and the field’s guidelines name them alongside the GLP-1 medications as legitimate additions to lifestyle care: the phentermine-topiramate combination and the naltrexone-bupropion combination.[7] Phentermine on its own is approved for shorter courses.[24] Each has its own profile, its own screening, and its own place — and which, if any, belongs in your plan is decided at the consult, not on this page.

Phentermine deserves a plain paragraph, because it’s the one men ask about. It is a Schedule IV controlled substance, and its FDA label approves it as a short-term adjunct — a few weeks — to a weight-reduction program built on exercise, behavior change, and calorie control.[24] It is not prescribed to men with a history of cardiovascular disease or uncontrolled high blood pressure, an overactive thyroid, glaucoma, a history of substance misuse, or use of an MAO inhibitor in the past two weeks, and the label is clear that if it stops working, the answer is to stop it, not to raise the dose.[24] At Dr. Vigor® clinics, phentermine — like every controlled substance — is prescribed only after an in-person evaluation, only when clinically appropriate, and only for as long as it is. We market the evaluation, never the drug.

Safety & Candor

Well studied, well understood — and we tell you all of it

The approved GLP-1 medications have been studied in tens of thousands of trial participants, and their side-effect profile is well described. Most side effects are gastrointestinal, mild to moderate, and concentrated in the weeks when the dose is being stepped up. In the pooled semaglutide trials, about four in ten participants reported nausea at some point — against fewer than two in ten on placebo — three in ten diarrhea, and a quarter vomiting or constipation — nearly all of it mild to moderate and transient, and fewer than one in twenty stopped treatment because of it.[25] That’s why the dose is escalated slowly, and why your clinician sets the pace rather than the calendar.

The common ones from the labels are plain: nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, fatigue, reflux, and injection-site reactions, with hair loss reported with tirzepatide.[4][3] The serious ones are rarer, and we name them anyway. Pancreatitis. Gallbladder disease — across 76 randomized trials, GLP-1 medications raised the risk of gallbladder or biliary problems by roughly a third overall, and more than doubled it in the weight-loss trials, with higher doses and longer use adding to it.[26] Dehydration severe enough to injure the kidneys. Low blood sugar when combined with insulin or certain diabetes medications. And a warning every surgeon and anesthesiologist needs to hear from you: these medications slow stomach emptying, and there have been rare reports of stomach contents entering the lungs during procedures under general anesthesia or deep sedation despite normal fasting — so tell every clinician who treats you that you’re on one.[4][3]

The boxed warning, in plain language. In rodent studies, this class of medication caused thyroid C-cell tumors, and it is not known whether it does so in humans.[4][3] The human evidence so far is mixed: a Scandinavian study of more than 145,000 users, compared with users of another diabetes medication, found no substantial increase in thyroid cancer over nearly four years, while a French study, also in people with diabetes, reported an increased risk, particularly after one to three years of use.[27][28] Because of that warning, these medications are not prescribed to anyone with a personal or family history of medullary thyroid carcinoma or the genetic syndrome MEN 2.[4][3] You’ll be asked. It matters.

One more, because you may have read about it. Earlier labels carried a warning about suicidal thoughts. In January 2026, after reviewing 91 placebo-controlled trials with more than 107,000 patients and a cohort of more than two million users, the FDA did not identify an increased risk and asked manufacturers to remove the warning[29] — consistent with large independent studies that found no signal, and in one case a lower risk.[30][31] If your mood changes on any medication, you tell your clinician. That rule doesn’t need a label.

Who should not. Beyond the thyroid history above, GLP-1 medications are not started in a man with a prior serious reaction to the medication, and they call for a careful conversation — and often a different plan — with a history of pancreatitis, active gallbladder disease, or serious stomach or bowel disease.[4][3] The non-GLP-1 options carry their own bars, named above.[24] Your clinician screens for all of it at the consult, because the right medication for the right man is the whole point — and saying no to the wrong man is the same standard.

Dr. Vigor Editorial Team

The Injections

B12 and lipotropic shots: a straight answer

Men ask about vitamin B12 shots and lipotropic (“lipo”) injections because the ads are everywhere. Here’s the straight answer, in three parts.

Vitamin B12 injection is FDA-approved for one thing: correcting a documented B12 deficiency caused by poor absorption.[32] That is worth checking in this audience — long-term metformin use and long-term use of acid-suppressing medications are both associated with low B12,[33][34] and low B12 has consequences that have nothing to do with weight. But in a man who isn’t deficient, B12 does nothing for weight or for performance: the NIH says supplementation has no benefit on performance in the absence of a deficit, and a two-year randomized trial of B-vitamin supplementation in adults over 65 found no significant effect on body weight, fat mass, or lean mass.[35][36] If your labs show you’re low, your clinician corrects the deficiency. If they don’t, we don’t sell you a shot.

Lipotropic injections — usually methionine, inositol, and choline, sometimes with B12 — are compounded products. They are not FDA-approved for weight loss, which means the FDA has not reviewed them for safety, effectiveness, or quality for that purpose,[17] and there are no controlled human trials showing that they produce weight loss. So we make no such claim, and we’d be suspicious of anyone who does.

Whether either injection belongs in your plan is your clinician’s call at the consult, based on your labs and your history — never a default, never an add-on at the front desk.

Candidacy

Who this is for — and the two other doors

The program is for adults with obesity, or with overweight and at least one weight-related condition — the population the approved medications are indicated for — as your clinician determines at the consult.[4] That’s the medical definition. The practical one is a man whose weight is affecting his health, his energy, or his life, who has done the reasonable things and is ready for real medicine. If you’re not sure you qualify, the consult is where that gets answered honestly.

Two other doors are open, and we’ll tell you plainly which one to walk through first. If you’re near a weight you can hold and the problem is a stubborn area that diet and training won’t touch, that’s a body-sculpting conversation, not a medication conversation — non-surgical fat reduction changes the shape of an area and does not produce weight loss.[37] See body sculpting for men And if your labs show low testosterone alongside excess weight, the two are often related: obesity and low testosterone frequently travel together, and in a meta-analysis of 24 studies, weight loss was associated with a rise in testosterone — the more weight lost, the larger the rise.[38][39] That doesn’t make weight loss a substitute for therapy, and it doesn’t make therapy a substitute for weight loss. It makes them a conversation worth having in the same room, which is the Calibrated TRT® conversation. See Calibrated TRT®

Metabolic support inside the peptide programs is its own conversation, separate from medical weight loss. See the peptide programs

The Evidence

What the trials found — both halves of the story

The encouraging half first. In the pivotal trial of semaglutide 2.4 mg — 1,961 adults with obesity or overweight and without diabetes, funded by Novo Nordisk — participants lost an average of 14.9% of their body weight over 68 weeks, against 2.4% on placebo.[40] In the pivotal trial of tirzepatide — 2,539 adults with obesity or overweight and without diabetes, funded by Eli Lilly — the average was 15.0% to 20.9% depending on dose, against 3.1% on placebo, over 72 weeks.[41] In an open-label head-to-head trial funded by Eli Lilly, the maker of tirzepatide, tirzepatide produced more weight loss than semaglutide.[42] Those are averages from trials that enrolled mostly women — seven or eight in ten participants in the maintenance trials[6][15] — and they describe people who continued treatment. Individual results vary, and no figure here is a promise about you.

The heart matters too. In a trial of more than 17,000 adults with established heart disease and obesity or overweight, without diabetes — mostly men, funded by Novo Nordisk — semaglutide reduced major cardiovascular events by about a fifth in relative terms, 6.5% of participants versus 8.0% on placebo, over about three years,[43] with weight loss that held over four years while treatment continued.[16] Individual results vary.

The honest half, at the same volume. When treatment stops, most of the weight comes back. In the semaglutide trial’s extension, participants who had lost an average of 17.3% regained most of it within a year off the medication, ending about 5.6% below where they started.[5] In the Eli Lilly-funded tirzepatide maintenance trial — 670 adults, mostly women — participants who had lost an average of 20.9% over 36 weeks and were then switched to placebo regained an average of 14.0% over the following year, while those who continued kept losing.[6] A similar Novo Nordisk-funded semaglutide trial — 803 adults, mostly women — showed the same pattern.[15] That is exactly why this program is built around habits and an off-ramp, not just a prescription. Individual results vary.

And the part the ads skip: the habits work on their own, too. In the NIH-funded Diabetes Prevention Program — 3,234 adults with elevated blood sugar — a lifestyle program aiming at a modest weight loss and 150 minutes of weekly activity cut the incidence of type 2 diabetes by more than half over about three years.[44] In a decade-long trial in adults with type 2 diabetes, intensive lifestyle intervention produced greater, sustained weight loss than standard care — though it did not reduce heart attacks and strokes.[45] The men and women who keep weight off for at least a year share identifiable habits: roughly an hour a day of physical activity, a consistent eating pattern, regular breakfast, and regular self-weighing.[46] The U.S. Preventive Services Task Force recommends intensive behavioral programs for every adult with obesity for the same reason.[47] Medication quiets the appetite while the habits are built. The habits are what keep the result.

Our Standard

Physician-supervised. FDA-approved. Honestly measured.

Dr. Vigor® clinics in California are 100% physician-owned, and medical weight loss here runs on the same rules as everything else we do. Evaluation and labs before any prescription. FDA-approved medication only, from state-licensed pharmacies. A dose set and adjusted by your own clinician, on your numbers. Nutrition and training guidance built for men, from a clinical team under physician supervision. And a plan for after, written into the program from day one.

We publish the parts that are easiest to leave out: that in the trials most of the lost weight came back after stopping, that some of what you lose will be lean mass and that training and protein are how you keep as much of it as you can, that the medications carry real warnings, and that some men will not be candidates at all. We’d rather earn the consult with a straight answer than win it with a big one.

FAQ

Questions, answered

Which weight-loss medications does Dr. Vigor® use?

Only FDA-approved medications, and never compounded ones. In the GLP-1 class, the FDA-approved options for weight management are Wegovy® (injection or tablet), Zepbound®, Foundayo™, and Saxenda®, and beyond the class they include phentermine and other FDA-approved options when they fit.[4][3][21][23][7] Which one — if any — is right for you is your clinician’s decision at the consult.

Isn’t Ozempic® the same drug as Wegovy®?

Same molecule, different approvals. Ozempic® and Wegovy® both contain semaglutide, and Mounjaro® and Zepbound® both contain tirzepatide — but Ozempic® and Mounjaro® are FDA-approved for type 2 diabetes, while Wegovy® and Zepbound® are the products approved for weight management.[4][3] At Dr. Vigor® clinics, weight-loss prescriptions use the products approved for weight loss, and every prescription decision is your clinician’s, made for your situation.

Do you prescribe compounded semaglutide or tirzepatide?

No. Compounded GLP-1 products are not FDA-approved, are not reviewed by the FDA for safety, effectiveness, or quality, and have generated hundreds of adverse-event reports, including dosing errors that led to hospitalization.[17] The shortages that once justified them ended in 2025.[18] Dr. Vigor® prescribes FDA-approved medication only, dispensed by state-licensed U.S. pharmacies.

What does the program cost, and what’s included?

You’ll know your full cost before you start — the program fee, and separately, what the medication itself costs, which depends on the product prescribed. Medication cost is not included in program fees unless we expressly say so. Call 949-570-0800 and ask — nobody will make you book to find out.

Do I have to come in, or can this be done online?

You come in. Every Dr. Vigor® program starts with a focused consult — virtual if you like — and then an in-person visit with vitals and bloodwork before any products or services. Medication is prescribed only after that evaluation, only when clinically appropriate, and only with a valid prescription. That’s slower than a questionnaire. It’s also medicine.

What are the side effects?

Mostly stomach-related, mostly mild to moderate, and mostly during the weeks the dose is being increased: nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, fatigue, and reflux.[4][3][25] Rarer, serious effects — pancreatitis, gallbladder disease, kidney injury from dehydration, and a boxed warning about thyroid tumors seen in rodent studies — are named plainly in the safety section above, along with who should not take these medications.

Will I regain the weight when I stop?

That depends on the plan. In the trials, most of the lost weight came back after participants stopped.[5][6] That’s exactly why this program includes the habits and the off-ramp from day one, and why your clinician sets the course for tapering or continuing rather than leaving you to guess. Individual results vary.

Will I lose muscle?

Some — and how much depends on how you eat and train while you lose it. Part of the weight lost on these medications is lean mass.[9][10] Resistance training and adequate protein are the two things the evidence says help preserve it during weight loss,[11][13] so they’re built into the program, and your progress is tracked by more than the scale. Individual results vary.

Am I a candidate? Who shouldn’t do this?

A licensed clinician decides at your consult. The approved medications are for adults with obesity, or overweight with a weight-related condition, and they are not prescribed to anyone with a personal or family history of medullary thyroid carcinoma or MEN 2.[4] A history of pancreatitis, active gallbladder disease, or serious digestive disease calls for a different conversation, and phentermine carries its own bars, including heart disease and uncontrolled blood pressure.[24] We screen carefully on purpose.

Is phentermine an option?

For some men, yes — after an in-person evaluation, when clinically appropriate, and for the short course its FDA label approves. Phentermine is a Schedule IV controlled substance approved as a short-term adjunct to a weight-reduction program, and it isn’t prescribed to men with a history of cardiovascular disease, uncontrolled high blood pressure, and several other conditions.[24] We market the evaluation, not the drug.

Do B12 or lipotropic injections help with weight loss?

No. Vitamin B12 injection is approved to correct a documented B12 deficiency — worth checking if you’ve been on metformin or acid-suppressing medication for years — and does nothing for weight in a man who isn’t deficient.[32][35][36] Lipotropic injections are compounded, are not FDA-approved for weight loss, and have no controlled human trials showing they produce weight loss, so we make no such claim.[17] Your clinician decides at the consult whether either fits your plan.

Does insurance cover this?

Dr. Vigor® is a concierge clinic group and does not bill insurance, which is part of why the pricing is plain. You’ll know your full cost before you start, and you’re welcome to call 949-570-0800 to walk through it before you book anything.

Citations & References

The research behind this page

Every clinical and regulatory statement on this page resolves to a verified source — peer-reviewed research listed in the National Library of Medicine’s PubMed index, a professional-society guideline, or an official U.S. regulatory record — and each reference was resolved and checked against that record during the build. Trial sponsorship is named where it exists. A citation is not an endorsement: no source here implies that any agency, journal, or company vouches for this clinic or any result. The numbered links in the text above lead here rather than off this site — each entry prints the record’s own address so you can look it up yourself.

  1. Emmerich SD, Fryar CD, Stierman B, Ogden CL. Obesity and severe obesity prevalence in adults: United States, August 2021–August 2023. NCHS Data Brief No. 508. National Center for Health Statistics, September 24, 2024. PMID: 39808758. https://www.cdc.gov/nchs/products/databriefs/db508.htm NCHS: 40.3% of U.S. adults had obesity in 2021–2023 — 39.2% of men — and prevalence was highest, 46.4%, at ages 40–59.
  2. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740–756. doi:10.1016/j.cmet.2018.03.001. PMID: 29617641. https://pubmed.ncbi.nlm.nih.gov/29617641/ Review: GLP-1 augments insulin and inhibits glucagon in response to meals, inhibits gastric emptying and food intake, and engages brain circuits that govern appetite.
  3. Eli Lilly and Company. ZEPBOUND® (tirzepatide) injection, prescribing information. Revised 04/2026. https://pi.lilly.com/us/zepbound-uspi.pdf Label: a GIP receptor and GLP-1 receptor agonist indicated, with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight with a weight-related comorbid condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity. Boxed warning for thyroid C-cell tumors observed in rats. Contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Starting dose 2.5 mg weekly for 4 weeks, increased in 2.5 mg steps after at least 4 weeks on a dose.
  4. Novo Nordisk Inc. WEGOVY® (semaglutide) injection and tablets, prescribing information. Revised 6/2026. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b Label: indicated, with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight with at least one weight-related comorbid condition. Boxed warning for thyroid C-cell tumors observed in rodents. Contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Injection initiated at 0.25 mg weekly and stepped up every 4 weeks. Warnings include acute pancreatitis, acute gallbladder disease, hypoglycemia, acute kidney injury from volume depletion, severe gastrointestinal reactions, and pulmonary aspiration during general anesthesia or deep sedation.
  5. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–1564. doi:10.1111/dom.14725. PMID: 35441470. https://pubmed.ncbi.nlm.nih.gov/35441470/ Extension of STEP 1, 327 participants followed for one year after stopping treatment: mean weight loss of 17.3% on semaglutide at week 68 fell to a net 5.6% loss at week 120 — most of the lost weight was regained within a year of stopping. Funded by Novo Nordisk.
  6. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38–48. doi:10.1001/jama.2023.24945. PMID: 38078870. https://pubmed.ncbi.nlm.nih.gov/38078870/ 670 adults (71% women) who lost a mean 20.9% on tirzepatide over a 36-week lead-in were then randomized to continue or switch to placebo for 52 weeks: −5.5% further change on tirzepatide versus +14.0% regain on placebo. Eli Lilly-sponsored.
  7. Grunvald E, Shah R, Hernaez R, et al. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology. 2022;163(5):1198–1225. doi:10.1053/j.gastro.2022.08.045. PMID: 36273831. https://pubmed.ncbi.nlm.nih.gov/36273831/ Guideline: strongly recommends adding pharmacotherapy to lifestyle intervention for adults with overweight or obesity who have had an inadequate response to lifestyle intervention alone, naming semaglutide 2.4 mg, liraglutide 3.0 mg, phentermine-topiramate ER, and naltrexone-bupropion ER for long-term management.
  8. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342–362. doi:10.1210/jc.2014-3415. PMID: 25590212. https://pubmed.ncbi.nlm.nih.gov/25590212/ Guideline: medications approved for chronic weight management are useful adjuncts to lifestyle change for patients who have not succeeded with diet and exercise alone.
  9. Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720–2729. doi:10.1111/dom.16275. PMID: 39996356. https://pubmed.ncbi.nlm.nih.gov/39996356/ DXA substudy of 160 SURMOUNT-1 participants (73% female): over 72 weeks, fat mass fell 33.9% and lean mass 10.9% on tirzepatide — of the weight lost, approximately 75% was fat and 25% was lean mass. Eli Lilly-sponsored study.
  10. Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26 Suppl 4:16–27. doi:10.1111/dom.15728. PMID: 38937282. https://pubmed.ncbi.nlm.nih.gov/38937282/ Review: across studies, lean-mass reductions range from roughly 15% or less of total weight lost to 40–60% in some studies; mitigation approaches, including muscle-preserving strategies used alongside GLP-1-based therapy, are reviewed.
  11. Binmahfoz A, Dighriri A, Gray C, Gray SR. Effect of resistance exercise on body composition, muscle strength and cardiometabolic health during dietary weight loss in people living with overweight or obesity: a systematic review and meta-analysis. BMJ Open Sport Exerc Med. 2025;11(3):e002363. doi:10.1136/bmjsem-2024-002363. PMID: 40909191. https://pubmed.ncbi.nlm.nih.gov/40909191/ Meta-analysis of 25 randomized trials: adding resistance exercise to dietary weight loss protected fat-free mass (moderate certainty), increased fat loss (high certainty), and increased strength, with no difference in total weight lost.
  12. Sardeli AV, Komatsu TR, Mori MA, Gáspari AF, Chacon-Mikahil MPT. Resistance training prevents muscle loss induced by caloric restriction in obese elderly individuals: a systematic review and meta-analysis. Nutrients. 2018;10(4):423. doi:10.3390/nu10040423. PMID: 29596307. https://pubmed.ncbi.nlm.nih.gov/29596307/ Meta-analysis of six randomized trials in older adults with obesity: resistance training prevented 93.5% of the lean-mass loss induced by caloric restriction.
  13. Leidy HJ, Clifton PM, Astrup A, et al. The role of protein in weight loss and maintenance. Am J Clin Nutr. 2015;101(6):1320S–1329S. doi:10.3945/ajcn.114.084038. PMID: 25926512. https://pubmed.ncbi.nlm.nih.gov/25926512/ Review: higher-protein diets of roughly 1.2–1.6 g of protein per kilogram per day, with about 25–30 g per meal, are associated with greater weight and fat loss and preservation of lean mass during energy restriction.
  14. Wycherley TP, Moran LJ, Clifton PM, Noakes M, Brinkworth GD. Effects of energy-restricted high-protein, low-fat compared with standard-protein, low-fat diets: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2012;96(6):1281–1298. doi:10.3945/ajcn.112.044321. PMID: 23097268. https://pubmed.ncbi.nlm.nih.gov/23097268/ Meta-analysis of 24 trials, 1,063 participants: higher-protein energy-restricted diets produced modestly greater weight and fat-mass loss and preserved more fat-free mass than standard-protein diets.
  15. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414–1425. doi:10.1001/jama.2021.3224. PMID: 33755728. https://pubmed.ncbi.nlm.nih.gov/33755728/ 803 adults (79% women) who lost a mean 10.6% in a 20-week run-in on semaglutide were randomized to continue or switch to placebo: −7.9% further change versus +6.9% regain over 48 weeks. Novo Nordisk-sponsored.
  16. Ryan DH, Lingvay I, Deanfield J, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024;30(7):2049–2057. doi:10.1038/s41591-024-02996-7. PMID: 38740993. https://pubmed.ncbi.nlm.nih.gov/38740993/ SELECT weight analysis (72.3% male): at 208 weeks, −10.2% with semaglutide versus −1.5% with placebo; clinically meaningful weight loss occurred in both sexes, and at week 104 the placebo-corrected loss was larger in women (−11.1%) than in men (−7.5%). Novo Nordisk-funded.
  17. U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Content current as of 06/15/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss FDA: compounded drugs are not FDA approved and are not reviewed for safety, effectiveness, or quality before marketing. As of May 31, 2026, FDA had received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide, including reports, some requiring hospitalization, that may relate to dosing errors. Patients should obtain a prescription and fill it at a state-licensed pharmacy.
  18. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Content current as of 04/01/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize FDA: the tirzepatide shortage was determined resolved on December 19, 2024 and the semaglutide shortage on February 21, 2025; the agency’s enforcement-discretion periods for compounded copies ended in the first half of 2025.
  19. U.S. Food and Drug Administration. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s. Press announcement, March 3, 2026. Content current as of 03/03/2026. https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s FDA: warning letters to thirty telehealth companies for claims implying sameness with FDA-approved products and for advertising compounded products under the firm’s own brand — the second group of such letters since the agency’s September 2025 crackdown on misleading direct-to-consumer pharmaceutical advertising.
  20. U.S. Food and Drug Administration. FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide. Press announcement, March 19, 2026. Content current as of 03/19/2026. https://www.fda.gov/news-events/press-announcements/fda-approves-fourth-product-under-national-priority-voucher-program-higher-dose-semaglutide FDA: a higher-dose Wegovy® injection (Wegovy® HD) approved for weight loss and long-term maintenance of weight loss in certain adults; gastrointestinal effects were the most common adverse reactions, and altered skin sensation occurred more often at the higher dose.
  21. Eli Lilly and Company. FOUNDAYO™ (orforglipron) tablets, prescribing information. Revised 7/2026. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62 Label: an oral, once-daily GLP-1 receptor agonist indicated to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight with a weight-related comorbid condition, with the class boxed warning and the same medullary-thyroid-carcinoma and MEN 2 contraindication.
  22. U.S. Food and Drug Administration. FDA Approves First New Molecular Entity Under National Priority Voucher Program. Press announcement, April 1, 2026. Content current as of 04/01/2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-new-molecular-entity-under-national-priority-voucher-program FDA: Foundayo™ (orforglipron), a GLP-1 receptor agonist in tablet form taken once daily, approved for use with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight with a weight-related comorbid condition.
  23. Novo Nordisk Inc. SAXENDA® (liraglutide) injection, prescribing information. Revised 6/2026. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143 Label: a once-daily GLP-1 receptor agonist indicated to reduce excess body weight in adults with obesity or overweight with a weight-related comorbid condition, with the class boxed warning and contraindications, and a labeled stopping rule — discontinue if at least 4% of baseline weight has not been lost after 16 weeks.
  24. Teva Pharmaceuticals USA. ADIPEX-P® (phentermine hydrochloride) tablets and capsules, CIV, prescribing information. Revised 3/2024. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5b2f9d8-2226-476e-9caf-9d41e6891c46 Label: phentermine is a Schedule IV controlled substance indicated as a short-term (a few weeks) adjunct in a weight-reduction regimen based on exercise, behavioral modification, and caloric restriction; contraindicated with a history of cardiovascular disease, uncontrolled hypertension, hyperthyroidism, glaucoma, agitated states, a history of drug abuse, MAOI use, pregnancy, and nursing; if tolerance develops the drug should be discontinued rather than the dose increased.
  25. Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24(1):94–105. doi:10.1111/dom.14551. PMID: 34514682. https://pubmed.ncbi.nlm.nih.gov/34514682/ Pooled STEP trial analysis: nausea in 43.9% (vs 16.1% placebo), diarrhea 29.7%, vomiting 24.5%, constipation 24.2%; most events mild to moderate (98.1%), transient, and clustered around dose escalation; 4.3% stopped treatment for gastrointestinal effects. Novo Nordisk-affiliated authorship.
  26. He L, Wang J, Ping F, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022;182(5):513–519. doi:10.1001/jamainternmed.2022.0338. PMID: 35344001. https://pubmed.ncbi.nlm.nih.gov/35344001/ Meta-analysis of 76 randomized trials, 103,371 patients: GLP-1 receptor agonist treatment was associated with a higher risk of gallbladder or biliary disease (relative risk 1.37), higher at higher doses, with longer use, and in weight-loss trials.
  27. Pasternak B, Wintzell V, Hviid A, et al. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ. 2024;385:e078225. doi:10.1136/bmj-2023-078225. PMID: 38683947. https://pubmed.ncbi.nlm.nih.gov/38683947/ Cohort study of 145,410 GLP-1 receptor agonist users versus 291,667 DPP-4 inhibitor users, mean follow-up 3.9 years: no substantially increased risk of thyroid cancer (hazard ratio 0.93) or medullary thyroid cancer (hazard ratio 1.19, wide confidence interval).
  28. Bezin J, Gouverneur A, Pénichon M, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023;46(2):384–390. doi:10.2337/dc22-1148. PMID: 36356111. https://pubmed.ncbi.nlm.nih.gov/36356111/ French nested case-control study in people with type 2 diabetes: GLP-1 receptor agonist use was associated with increased risk of all thyroid cancer (hazard ratio 1.58) and medullary thyroid cancer (hazard ratio 1.78), particularly after 1–3 years of use.
  29. U.S. Food and Drug Administration. FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications. Drug Safety Communication, January 13, 2026. Content current as of 04/03/2026. https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp FDA: its evaluation — a meta-analysis of 91 placebo-controlled trials with 107,910 patients and a cohort study of more than 2.2 million users — did not identify an increased risk of suicidal ideation or behavior with GLP-1 receptor agonists, and FDA asked manufacturers to remove the warning from the labeling of Saxenda®, Wegovy®, and Zepbound®.
  30. Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med. 2024;30(1):168–176. doi:10.1038/s41591-023-02672-2. PMID: 38182782. https://pubmed.ncbi.nlm.nih.gov/38182782/ Electronic-health-record cohort of 240,618 patients with overweight or obesity: semaglutide was associated with a lower risk of first-time (hazard ratio 0.27) and recurrent (0.44) suicidal ideation than non-GLP-1 anti-obesity medications, replicated in 1.6 million patients with type 2 diabetes. NIH-funded.
  31. Ueda P, Söderling J, Wintzell V, et al. GLP-1 receptor agonist use and risk of suicide death. JAMA Intern Med. 2024;184(11):1301–1312. doi:10.1001/jamainternmed.2024.4369. PMID: 39226030. https://pubmed.ncbi.nlm.nih.gov/39226030/ Swedish and Danish cohort of 124,517 GLP-1 receptor agonist initiators versus 174,036 SGLT2-inhibitor initiators: no increase in suicide death (hazard ratio 1.25, confidence interval crossing 1), and no increase in suicide or self-harm combined or in depression and anxiety diagnoses.
  32. Cyanocobalamin Injection, USP 1000 mcg/mL, prescribing information. Revised December 2023. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a66eb3c4-3e1d-4d49-b963-4fa2334cc9b6 Label: indicated for vitamin B12 deficiencies due to malabsorption — pernicious anemia, gastrointestinal disease or surgery, and related causes. No weight-loss or energy indication. Increased requirements can usually be met with oral supplementation.
  33. Aroda VR, Edelstein SL, Goldberg RB, et al.; Diabetes Prevention Program Research Group. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016;101(4):1754–1761. doi:10.1210/jc.2015-3754. PMID: 26900641. https://pubmed.ncbi.nlm.nih.gov/26900641/ Long-term metformin use was associated with biochemical B12 deficiency — 4.3% versus 2.3% at five years — with risk rising by about 13% per year of use.
  34. Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310(22):2435–2442. doi:10.1001/jama.2013.280490. PMID: 24327038. https://pubmed.ncbi.nlm.nih.gov/24327038/ Case-control study of 25,956 people with B12 deficiency and 184,199 controls: two or more years of proton-pump-inhibitor use (odds ratio 1.65) or H2-blocker use (1.25) was associated with B12 deficiency.
  35. National Institutes of Health, Office of Dietary Supplements. Vitamin B12: Fact Sheet for Health Professionals. Updated July 2, 2025. https://ods.od.nih.gov/factsheets/VitaminB12-HealthProfessional/ NIH: vitamin B12 supplementation appears to have no beneficial effect on performance in the absence of a nutritional deficit; metformin and acid-suppressing medications can reduce B12 absorption.
  36. Oliai Araghi S, Kiefte-de Jong JC, van Dijk SC, et al. B-vitamins and body composition: integrating observational and experimental evidence from the B-PROOF study. Eur J Nutr. 2020;59(3):1253–1262. doi:10.1007/s00394-019-01985-8. PMID: 31076856. https://pubmed.ncbi.nlm.nih.gov/31076856/ Randomized trial of two years of folic acid plus vitamin B12 supplementation in 2,919 adults aged 65 and older: no significant effect on BMI, fat mass, or fat-free mass.
  37. U.S. Food and Drug Administration. Non-Invasive Body Contouring Technologies. Content current as of October 15, 2025. https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/non-invasive-body-contouring-technologies FDA: non-invasive body contouring does not treat obesity and will not result in weight loss.
  38. Corona G, Vignozzi L, Sforza A, Mannucci E, Maggi M. Obesity and late-onset hypogonadism. Mol Cell Endocrinol. 2015;418 Pt 2:120–133. doi:10.1016/j.mce.2015.06.031. PMID: 26143633. https://pubmed.ncbi.nlm.nih.gov/26143633/ Review: obesity and male hypogonadism are often associated, and treating obesity is an efficient treatment for obesity-induced hypogonadism.
  39. Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol. 2013;168(6):829–843. doi:10.1530/EJE-12-0955. PMID: 23482592. https://pubmed.ncbi.nlm.nih.gov/23482592/ Meta-analysis of 24 studies: weight loss was associated with a rise in total testosterone — about 2.9 nmol/L with a low-calorie diet and about 8.7 nmol/L after bariatric surgery — and the amount of weight lost was the strongest determinant of the rise.
  40. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183. PMID: 33567185. https://pubmed.ncbi.nlm.nih.gov/33567185/ Randomized trial, 1,961 adults with obesity or overweight without diabetes, 68 weeks. Mean body-weight change −14.9% with semaglutide 2.4 mg versus −2.4% with placebo. Nausea and diarrhea were the most common adverse events, typically transient and mild to moderate. Funded by Novo Nordisk.
  41. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038. PMID: 35658024. https://pubmed.ncbi.nlm.nih.gov/35658024/ Randomized trial, 2,539 adults with obesity or overweight without diabetes, 72 weeks. Mean body-weight change −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) with tirzepatide versus −3.1% with placebo. Gastrointestinal adverse events were the most common, mostly mild to moderate and concentrated during dose escalation. Supported by Eli Lilly.
  42. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26–36. doi:10.1056/NEJMoa2416394. PMID: 40353578. https://pubmed.ncbi.nlm.nih.gov/40353578/ Open-label head-to-head trial, 751 adults, 72 weeks: −20.2% with tirzepatide versus −13.7% with semaglutide 2.4 mg. Funded by Eli Lilly — the maker of tirzepatide.
  43. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221–2232. doi:10.1056/NEJMoa2307563. PMID: 37952131. https://pubmed.ncbi.nlm.nih.gov/37952131/ 17,604 adults with established cardiovascular disease and obesity or overweight, without diabetes: a primary cardiovascular event occurred in 6.5% on semaglutide 2.4 mg versus 8.0% on placebo (hazard ratio 0.80). Funded by Novo Nordisk.
  44. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403. doi:10.1056/NEJMoa012512. PMID: 11832527. https://pubmed.ncbi.nlm.nih.gov/11832527/ Randomized trial, 3,234 adults with elevated glucose: a lifestyle program aiming at 7% weight loss and 150 minutes of weekly activity reduced the incidence of type 2 diabetes by 58% versus placebo. NIH-funded.
  45. Look AHEAD Research Group; Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–154. doi:10.1056/NEJMoa1212914. PMID: 23796131. https://pubmed.ncbi.nlm.nih.gov/23796131/ Randomized trial, 5,145 adults with type 2 diabetes and overweight or obesity: intensive lifestyle intervention produced greater weight loss (8.6% vs 0.7% at one year, 6.0% vs 3.5% at study end) but did not reduce cardiovascular events. NIH-funded.
  46. Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr. 2005;82(1 Suppl):222S–225S. doi:10.1093/ajcn/82.1.222S. PMID: 16002825. https://pubmed.ncbi.nlm.nih.gov/16002825/ National Weight Control Registry: people who have kept at least 10% of body weight off for at least a year report roughly an hour a day of physical activity, a lower-calorie eating pattern, regular breakfast, regular self-weighing, and a consistent eating pattern.
  47. US Preventive Services Task Force; Curry SJ, Krist AH, Owens DK, et al. Behavioral weight loss interventions to prevent obesity-related morbidity and mortality in adults: US Preventive Services Task Force recommendation statement. JAMA. 2018;320(11):1163–1171. doi:10.1001/jama.2018.13022. PMID: 30326502. https://pubmed.ncbi.nlm.nih.gov/30326502/ Recommendation (grade B): clinicians should offer or refer adults with a BMI of 30 or higher to intensive, multicomponent behavioral interventions, which reduce the incidence of type 2 diabetes among adults with obesity.

Getting Started

Start with a consult. FINISH STRONG®.

Getting started is simple.

  1. Step 01

    Talk

    A focused consult — virtual if you like.

  2. Step 02

    Test

    An in-person visit: vitals and bloodwork before any products or services.

  3. Step 03

    Tune

    Proven protocols do the groundwork. Your clinician makes the call — your dose, adjusted over time to your labs and how you actually feel. Prescribed only when clinically appropriate, and monitored like medicine, because it is.

Book a consult Call 949-570-0800

Individual results vary. Medication only when clinically appropriate.

Dr. Vigor® clinics in California are 100% physician-owned. Prescription weight-loss medications are prescribed only when clinically appropriate after evaluation by a licensed clinician; a medical consultation and prescription are required before any medication is provided, and every program begins with an in-person visit with vitals and bloodwork. Dr. Vigor prescribes FDA-approved medications only, dispensed by state-licensed U.S. pharmacies with a valid prescription; no compounded GLP-1 medications are offered or prescribed. Phentermine and related agents are controlled substances, prescribed only after in-person evaluation and only for as long as clinically appropriate. Vitamin B12 injection is prescribed only for a documented deficiency; lipotropic injections are compounded products that are not FDA-approved for weight loss, and no weight-loss benefit is claimed for any injection. Weight-loss outcomes vary by individual and are not guaranteed; no amount or rate of weight loss is typical or promised, and figures cited from published trials describe trial participants, not this program. Not all men are candidates. Treatment plans are set by the patient’s own licensed clinician, who alone determines candidacy, medication, dose, and course of treatment — protocols inform that judgment and never replace it. Program pricing is stated before enrollment; medication cost is separate from program fees unless expressly stated. Dr. Vigor is a concierge clinic group and does not bill insurance. Services available in California at Dr. Vigor clinic locations. Wegovy®, Ozempic®, and Saxenda® are registered trademarks of Novo Nordisk A/S. Zepbound® and Mounjaro® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. Foundayo™ is a trademark of Eli Lilly and Company. Dr. Vigor is not affiliated with or endorsed by these companies.

Dr. Vigor® clinics in California are 100% physician-owned. Prescription weight-loss medications are prescribed only when clinically appropriate after evaluation by a licensed clinician; a medical consultation and prescription are required before any medication is provided, and every program begins with an in-person visit with vitals and bloodwork. Dr. Vigor prescribes FDA-approved medications only, dispensed by state-licensed U.S. pharmacies with a valid prescription; no compounded GLP-1 medications are offered or prescribed. Phentermine and related agents are controlled substances, prescribed only after in-person evaluation and only for as long as clinically appropriate. Vitamin B12 injection is prescribed only for a documented deficiency; lipotropic injections are compounded products that are not FDA-approved for weight loss, and no weight-loss benefit is claimed for any injection. Weight-loss outcomes vary by individual and are not guaranteed; no amount or rate of weight loss is typical or promised, and figures cited from published trials describe trial participants, not this program. Not all men are candidates. Treatment plans are set by the patient’s own licensed clinician, who alone determines candidacy, medication, dose, and course of treatment — protocols inform that judgment and never replace it. Program pricing is stated before enrollment; medication cost is separate from program fees unless expressly stated. Dr. Vigor is a concierge clinic group and does not bill insurance. Services available in California at Dr. Vigor clinic locations. Wegovy®, Ozempic®, and Saxenda® are registered trademarks of Novo Nordisk A/S. Zepbound® and Mounjaro® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. Foundayo™ is a trademark of Eli Lilly and Company. Dr. Vigor is not affiliated with or endorsed by these companies.

BookCall